Karine Laulagnier

Karine Laulagnier has worked in the field of biotechnology since 2000. Karine began their career as a PhD student at INSERM U563, Université Paul Sabatier, where they studied nanovesicles, "exosomes" secreted by immune cells and involved in anti-tumor response. During this time they characterized their structure and biogenesis, developed new protocols in biochemistry and fluorescence microscopy, and tracked their transport between immune cells. In 2004, they moved to Geneva University, Switzerland, as a Post-Doctoral Researcher. In 2010, they became an R&D Engineer at ENS Lyon, where they studied exosomes that transport prion infectious diseases (Creutzfeld-Jacob). This work resulted in one publication. In 2012, they became a Project Manager at Grenoble Institute of Neuroscience. In 2016, they completed an internship at SYNTHELIS. In 2017, they returned to PDC*line Pharma as a Scientific Writer and Consultant, where they reported R&D results obtained by specialists of immunooncology developing cell-based therapy against cancer. In this role, they were responsible for result analysis, proposition of perspectives and scientific watch. In 2018, they joined GENEL The RNAi Switch as a Chef de Projet en Biologie, where they were responsible for understanding client needs and proposing innovative solutions.

Karine Laulagnier obtained their Doctor of Philosophy (PhD) in Cell Biology and Biochemistry from Universit\u00e9 Paul Sabatier Toulouse III between 1998 and 2004. In 2018, they obtained a certification in GMP and GLP adapted to R&D and QC. In 2013, they obtained a Level 1 certification in animal experimentation from Communaut\u00e9 Universit\u00e9 Grenoble Alpes.